Envestnet Asset Management
BCYC

Envestnet Asset Management’s Bicycle Therapeutics BCYC Stock Holding History

Envestnet Asset Management’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12,420
Closed -$105K – 4438
2025
Q1 		$105K Buy
+12,420
New +$146K ﹤0.01% 4231
2022
Q2 		– Sell
-36,164
Closed -$1.59M – 3922
2022
Q1 		$1.59M Sell
36,164
-5,128
-12% -$239K ﹤0.01% 2350
2021
Q4 		$2.51M Sell
41,292
-2,004
-5% -$111K ﹤0.01% 2017
2021
Q3 		$1.8M Buy
43,296
+631
+1% +$22.1K ﹤0.01% 2149
2021
Q2 		$1.29M Buy
+42,665
New +$1.29M ﹤0.01% 2354

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Envestnet Asset Management's BCYC Position: Q2 2025 in Review

Envestnet Asset Management sold out of Bicycle Therapeutics (BCYC) in Q2 2025, closing a stake of 12,420 shares — an estimated $105K sold.

Envestnet Asset Management first reported a position in BCYC in Q2 2021 and held it in 5 quarters. The position peaked at $2.51M in Q4 2021. 110 funds tracked by Wall St. Rank hold BCYC as of Q2 2025.

  • Envestnet Asset Management reported no remaining Bicycle Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Envestnet Asset Management sold 12,420 Bicycle Therapeutics shares in Q2 2025, an estimated $105K.
  • Envestnet Asset Management first reported a position in Bicycle Therapeutics in Q2 2021 and held it in 5 quarters.
  • Envestnet Asset Management's Bicycle Therapeutics position peaked at $2.51M in Q4 2021.
  • 110 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2025.

Based on Envestnet Asset Management's 13F filing for Q2 2025, filed 1 Aug 2025.